

PERSONAL EXPLANATION

HON. JOE WILSON

OF SOUTH CAROLINA

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Mr. WILSON of South Carolina. Madam Speaker, I was unavoidably detained on June 14, 2022. Had I been present, I would have voted NAY on Roll Call No. 25.

HONORING SAGE LADIEU

HON. CHRIS PAPPAS

OF NEW HAMPSHIRE

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Mr. PAPPAS. Madam Speaker, I rise today in recognition of Sage Ladieu, who is being honored for his retirement from the military. Sage first answered the call to service in 1992, when he enlisted in the U.S. Navy as an aviation firefighter in California. Over the next 29 years, he moved up the ranks and most recently served as Command Sergeant Major for the 54th troop Command Brigade, providing guidance on the training, development, standards, traditions, discipline and welfare of the enlisted soldiers. Throughout his various roles in New Hampshire, across the country, and overseas, Sage had a profound impact on the lives of countless others.

Prior to his work as Command Sergeant Major for the 54th troop, Sage served as a Senior Enlisted Leader for both the 195th Regiment and the New Hampshire Army National Guard Recruiting and Retention Battalion. His responsibilities included supervising and mentoring staff, instructors, and recruiters in the implementation of focused and effective programs.

Despite being deployed to Saudi Arabia in 1993 and Iraq in 2004, Sage never wavered in his commitment to bettering Granite State communities. He worked to connect with younger generations as a Noncommissioned Recruiting Officer and a Professor of Military Science at the University of New Hampshire ROTC. He has continuously served as a supervisor, recruiter, mentor, and friend to so many in the community. Sage has worked tirelessly for his state and country and has rightfully earned numerous service medals and commendations.

On behalf of my constituents in New Hampshire's First Congressional District, I want to thank Sage for his dedication and wish him the best in his well-deserved retirement. I congratulate him again on his incredible career, and I thank him for all that he has done to keep our country safe.

RECOGNIZING ARNOLD "ARNIE" NETTEKOVEN

HON. MIKE GALLAGHER

OF WISCONSIN

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Mr. GALLAGHER. Madam Speaker, I rise today to recognize the life of a remarkable man: Arnold "Arnie" Nettekoven. A military veteran, retired Patrolman, and the first-ever

historian at the Appleton Police Department, Arnie has dedicated his life to serving his nation and community.

Born and raised in Black Creek, Wisconsin, Arnie grew up working on his family farm before enlisting in the Marine Corps and serving in the Korean War. After returning home to Northeast Wisconsin, Arnie was sworn in as a Patrolman at the Appleton Police Department on April 1st, 1960. After 30 years of service to the Appleton Police Department, Arnie continued to serve his community in several capacities including becoming the first Special Investigator in the Outagamie County District Attorney's Office. Through his many roles, Arnie's commitment and love for his community never wavered.

Arnie continued his contribution to the Appleton Police Department after retirement as the first-ever Department Historian. During his time as the historian, Arnie authored over 700 pages detailing the outstanding history of the Appleton Police Department and the Fox Valley. Arnie's commitment and dedication to his role led to the Appleton Police Department Military Tribute Wall and Appleton Police Benevolent Association Police Museum. Arnie's hard work did not go unnoticed as he received recognition as "Volunteer of the Year" for his efforts to document the remarkable history of the Appleton Police Department in 2018. Arnie's thoughtfulness and generosity will certainly be missed by many. However, the impact he has left through his work will carry on for many generations to come.

Madam Speaker, today the people of Northeast Wisconsin thank Arnie for his extraordinary commitment and service to his community. My thoughts and prayers go out to his family and to all of the lives he touched.

PERSONAL EXPLANATION

HON. ANTHONY GONZALEZ

OF OHIO

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Mr. GONZALEZ of Ohio. Madam Speaker, on Roll Call No. 267, I mistakenly voted Nay when I intended to vote Yea.

HOMETOWN HERO—JAN HABERER

HON. BETH VAN DUYN

OF TEXAS

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Ms. VAN DUYN. Madam Speaker, I rise today to recognize Jan Haberer, a Carrollton native, for her relentless fight to raise awareness for Alzheimer's.

Jan is no stranger to service. Her father was a World War II veteran, her son is currently in the Navy, and according to her friends, she "serves in many ways in the community."

After being diagnosed with mild cognitive impairment in 2013, Jan was forced to end her illustrious career as a missile defense engineer for Texas Instruments. However, Jan viewed this "not as a death sentence, but a life sentence to help as many people as she could."

Following her diagnosis, Jan began raising awareness and much-needed funding for the

Alzheimer's Association. With her husband Randy, she eventually started her own Walk to End Alzheimer's team, called "Jandy's Clan." Named after the partnership between Jan and Randy, this team is comprised of close friends, family, and dozens of passionate supporters.

Each year, Jandy's Clan participates in the Walk to End Alzheimer's, which helped her team become a top Dallas fundraiser in 2021. This incredible feat has gone a long way in Alzheimer's care, support, research, awareness, and advocacy. Furthermore, Jandy's Clan partners with the nonprofit, Secure Our Seniors' Safety, to ensure residents in senior living facilities are secure from criminal activity.

Jan's resilience in the face of adversity is not only an inspiring story, but it has benefited North Texas and all those suffering from Alzheimer's. I thank Jan, and hope she keeps up the hard work in her mission to fight Alzheimer's.

HONORING THE LIFE AND SERVICE OF THE HONORABLE ALAN ROSENFELD

HON. MIKE GARCIA

OF CALIFORNIA

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Mr. GARCIA of California. Madam Speaker, I rise today to remember the life and service of the Honorable Alan Rosenfield, who served for more than 15 years as a judge for the Los Angeles County Superior Court. Throughout his life and career, Judge Rosenfield exemplified what it meant to be a public servant with dignity, honor, and integrity.

Growing up in the San Fernando Valley, Alan was an exemplary student, charming friend, and dedicated son. Returning to Los Angeles after spending his college years in Iowa, Alan first began his life of service by joining the Los Angeles County Sheriff Department, one of the most storied and prestigious law enforcement agencies in California. While protecting and serving the citizens of Los Angeles County, he worked hard to also obtain a law degree, being admitted to the California Bar in 1981. After becoming an attorney, Alan continued his career as a Deputy District Attorney, enforcing the law and prosecuting dangerous criminals.

In 1990, Alan became the Honorable Judge Rosenfield after being appointed to the Newhall Municipal Court by California Governor George Deukmejian. He was later elevated to the Los Angeles County Superior Court in 2000, where he served for 17 years and had jurisdiction over cases in Santa Clarita and the Antelope Valley. As a judge, Rosenfield applied the law fairly and equally, fostering a justice system that upheld the values of our Constitution while also protecting the freedoms and security of law-abiding citizens. Even after his retirement, he continued to serve as an assigned judge and remained an active member of the Santa Clarita community, continuing to give back and devote time to charitable causes. Serving in the U.S. Army Reserves for nearly three decades, Judge Rosenfield was the recipient of the distinguished Judge Advocates Association Outstanding Career Armed Services Attorney Award.

Although he has left us too soon, the impact of Judge Alan Rosenfield's life will not soon be forgotten. Our communities are safer and our lives richer because of the life and service of Judge Rosenfield. We will continue to keep the Rosenfield family in our prayers, and we are thankful that our community was blessed enough to have Alan as a leader in the justice system.

TRIBUTE TO JEAN MCCOWN ON
HER RETIREMENT

HON. ANNA G. ESHOO

OF CALIFORNIA

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Ms. ESHOO. Madam Speaker, I rise today to honor Jean McCown, her career in public service, and as Associate Vice President of Government Affairs at Stanford University. Jean is a graduate of the University of Michigan and Boalt Hall Law School. Before joining Stanford in 2004, she was a partner at the law firm of Ritchey Fisher Whitman & Klein, where she focused on land use, environmental and real estate matters.

Jean was a member of the Palo Alto City Council from 1990 to 1998 and served as mayor in 1993. She previously served on the Palo Alto Planning Commission and on regional transportation committees including the CalTrain Joint Powers Board and the Metropolitan Transportation Commission.

Jean McCown served on the board of the Greenbelt Alliance for many years and is now a board member of the Palo Alto Community Foundation and Alta, formerly the Palo Alto Housing Corporation.

The honors she has earned include the John W. Gardner Leadership Award in 1994 from American Leadership Forum Silicon Valley, and the Palo Alto Chamber of Commerce Athena Award in 2004.

As Associate Vice President within the Office of Government Affairs at Stanford, Jean McCown focused on the University's government and community affairs efforts and initiatives at the city, county and state level. She maintained relationships with community-based organizations, government officials, local businesses and citizens to support effective communication and dialogue within the Stanford community and between Stanford and its neighbors. While at Stanford she provided strategic leadership for the Searsville Watershed Restoration project and provided strategic guidance for the Middle Plaza Housing Project in Menlo Park. She helped build supportive relationships with the Palo Alto Unified School District and secured the fire services contract between Stanford and the Palo Alto Fire Department. Jean led multiple General Use Permit negotiations with Santa Clara County, provided strategic guidance for the Hospitals Renewal projects for the Stanford adult and children's hospitals, and helped spearhead the Palo Alto Mayfield agreement creating new public playing fields and housing for the City.

Madam Speaker, I ask the entire House of Representatives to join me in honoring Jean McCown for her extraordinary work and in wishing her every blessing in her well-deserved retirement.

HOMETOWN HERO—JEWISH
COMMUNITY CENTER OF DALLAS

HON. BETH VAN DUYNE

OF TEXAS

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Ms. VAN DUYNE. Madam Speaker, I rise today to recognize the Jewish Community Center of Dallas, which has gone above and beyond to better our community.

The JCC's mission is to bring the North Texas Jewish community together with their incredible facilities and programs, however they have done so much more than that.

Each year, the JCC provides over 18,000 hot meals to North Texan seniors, regardless of race or religion. As the pandemic loomed, the JCC's resolve was unwavering. They continued their senior meal service with an innovative drive-thru feature to keep seniors safe and well fed.

The Jewish Community Center's compassion and service to its community should serve as an inspiration to all North Texans. I thank the JCC for going above and beyond to ensure North Texas is a brighter place to live every single day.

PASSAGE OF H.R. 7667, THE FOOD
AND DRUG AMENDMENTS OF 2022

HON. PRAMILA JAYAPAL

OF WASHINGTON

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 15, 2022

Ms. JAYAPAL. Madam Speaker, I rise today on the passage of H.R. 7667 the "Food and Drug Amendments of 2022." Though I am grateful for many of the provisions in this bipartisan legislation, I have strong concerns that this bill does not go far enough to protect the American people—both patients and their doctors. This reauthorization, only occurring every five years, is one of our greatest opportunities to hold the pharmaceutical industry accountable and to the highest standards possible to ensure access and protection for patients across the country.

Typically, this routine reauthorization of user fees is coupled with incentives directed toward the pharmaceutical and medical device industry. With each reauthorization to date, we have seen the increased adoption of expedited review pathways leaving patients and their doctors more uncertain that FDA approved treatments are truly effective or safe. Often, these new pathways that hasten FDA's regulatory review are coupled with financial incentives including exclusivity periods that prolong high monopoly prices such that the American public is paying more for less. Last year's controversial approval of the Alzheimer's disease drug, aducanumab (Aduhelm) laid bare this reality when the FDA approved this drug under the accelerated approval pathway despite harms including brain bleeding and swelling as well as uncertain clinical benefit. This shifted the focus of this year's user fee reauthorization efforts away from shortening FDA review times for new health technologies to reforms to reinstate public trust into FDA's approval process.

FDA's accelerated approval pathway can be an important way for promising drugs to reach patients. But pharmaceutical corporations

have largely failed to uphold their end of the bargain of completing critical studies to confirm that these drugs are truly beneficial. Instead, accelerated approval is being used by Big Pharma to drive further profits at the expense of patient safety and Medicare spending. Although H.R. 7667 would allow for greater FDA oversight of the accelerated approval pathway, this bill should have included much stronger reforms for accelerated-approval drugs.

This bill should have made sure that FDA publicly engages with their advisory committees instead of industry sponsors behind closed doors. Recent studies have found that FDA has convened these independent experts less frequently—between 2010 and 2021, FDA went from hearing these groups for 55 percent of approved drugs to just 6 percent. Transparency is paramount to ensuring trust in our government institutions. We should codify that meetings are made public and nothing should obscure a patient's ability to see how and why a therapeutic approval was granted.

Moreover, the bill should ensure that lower standards of evidence cannot be accepted to approve a drug. Clarification is needed to ensure that Real World Evidence (RWE) is appropriately used to augment the post-approval studies that prove therapies approved are truly effective and research has shown that RWE has demonstrated promise for complementing clinical trials but not replacing them. When it comes to the safety of our constituents, we must ensure that speedy access does not eclipse safety.

A recent study published in JAMA Health Forum explored how much Medicare and Medicaid spend on drugs granted accelerated approval by the FDA both before and after the drug's clinical benefit is confirmed. The study found that for the 38 drugs granted accelerated approval by the FDA between 2012 and 2017:

CMS spent almost \$70 billion through 2020 on these drugs;

just over \$50 billion (75 percent) was spent after the accelerated approval drugs were converted to standard approval following completion of their required confirmatory trials; but

almost 60 percent (\$40 billion) of this spending was for drugs with confirmatory trials evaluating surrogate endpoints instead of assessing meaningful clinical endpoints demonstrating the effect of these drugs on how patients feel, function, or survive.

In addition, this bill should squarely place patient safety at its core and mandate the automatic withdrawal of drugs, preliminarily approved under accelerated approval, that fail to prove efficacy. Not explicitly mandating that approval should expire one year after any target date of study completion, and in no case later than five years after the product is approved unless certain criteria relative to post approval studies are achieved, is a significant concession to the pharmaceutical industry that puts patients and payers at risk of prolonged medical and financial harms. There should be no barriers to removing a drug that at best is ineffective and at worst dangerous.

Another troubling inclusion in the approved measure are additional provisions that would empower a sponsor company to request a meeting with the FDA Commissioner, a public comment period followed by responses by the agency, and a convening of the advisory committee to review the agency's request for withdrawal, wasting precious time. Rather, the